Genes encoding the core binding factor (CBF) ␣2 (AML1, RUNX1) and ␤ subunits are amongst the commonest targets of chromosomal rearrangements in acute myeloid leukemia (AML), which include t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22), leading to formation of AML1-ETO and CBF␤-MYH11 fusion genes, respectively (reviewed in Friedman 1 ). AML cases with t(8;21) and inv(16)/ t(16;16) have been found to have a relatively favorable prognosis, characterized by high complete remission rates associated with low levels of resistant disease and superior overall survival.
Over the last few years it has become apparent that a proportion of AML cases have an underlying AML1-ETO or CBF␤-MYH11 fusion gene in the apparent absence of the classic t(8;21) or inv(16)/t(16;16), respectively. [9] [10] [11] [12] [13] [14] [15] [16] There are a number of potential reasons for this, which may be classified into the following subgroups:
1 Cytogenetic failures due to insufficient and/or poor quality metaphases. 2 Reporting of spuriously normal karyotypes due to sampling of residual normal marrow elements. 3 Insertions, in which the extent of inserted chromosomal material is typically below the resolution detectable by conventional karyotype analysis or chromosome paints, such that chromosomes 8 and 21 or 16, respectively, appear normal. 4 Simple variants, in which conventional cytogenetic analysis suggests a translocation between 16q22 or 16p13 and another chromosome in those with CBF␤-MYH11 gene fusions, or between 8q22 or 21q22 and another chromosome in which the AML1-ETO fusion results from the combination of an insertion and translocation. In some instances, however, cases appearing as simple variants involving 21q22 are true alternative translocations whereby AML1 is fused to other potential partner genes including EAP/MDS1/EVI1 and MTG16 generated by t(3;21)(q26;q22) 1 and t(16;21)(q24;q22), 17 respectively. 5 Complex rearrangements, including three-way translocations.
The precise frequency of insertions, simple variants and more complex rearrangements has not been firmly established amongst patients with molecular evidence of an underlying AML1-ETO or CBF␤-MYH11 gene fusion, as cytogenetics, RT-PCR and metaphase FISH using appropriate probes have rarely been combined. However, by analogy, analysis of 186 consecutive patients with PML-RAR␣-positive acute promyelocytic leukemia (APL) entered into the UK Medical Research Council (MRC) ATRA trial showed that 15% lack the t(15;17) due to cytogenetic failures (9%), insertions (4%) or more complex rearrangements (2%), 18 which is in accordance with data from the European Working Party. 19 As exemplified by the reports by Rowe et al 20 and Sarriera et al, 21 studies evaluating the role of molecular screening in AML to date have reported differing rates of detection of AML1-ETO and CBF␤-MYH11 in cases lacking the classic t(8;21) or inv(16)/t(16;16), respectively (see Tables 1 and 2 it should be born in mind that the studies detailed in Tables 1 and 2 are relatively small. This precludes reliable determination of the precise frequency of cryptic CBF gene rearrangements in AML and raises the possibility that the observed differences may in some instances have arisen by chance. Nevertheless, in interpreting such studies it is important to consider various factors that could have a significant bearing upon the relative frequency of cases with cryptic CBF gene rearrangements reported. A recent study by the CALGB group which considered a prospective parallel molecular and cytogenetic analysis in 284 adults with de novo AML has provided some insights into these issues highlighting the importance of central cytogenetic review. 22 In this study 19% of patients with a confirmed AML1-ETO gene fusion and successful cytogenetic analysis were found to lack the t(8;21); whilst consideration of initial cytogenetic examination suggested that 15% cases with a CBF␤-MYH11 fusion lacked the inv (16) (16) is a notoriously subtle cytogenetic abnormality, which may be difficult or impossible to detect in the presence of suboptimal metaphase spreads. In some multicenter studies, detection rates may be reduced by lack of central karyotype review and/or prolonged transit times to laboratories engaged in central cytogenetic analysis, leading to an apparent increase in cases reported as having 'cryptic' rearrangements. This may have contributed to the relatively high frequency of 'cryptic' CBF␤-MYH11 rearrangements in the report from the UK MRC, 23 since the rate of cytogenetically detected inv (16) in children and younger adults entered into the MRC AML10 trial was found to be relatively low (4%) 3 in comparison to other studies (reviewed in Mró zek 24 ). Variation in techniques between laboratories may also contribute to the reported differences in frequencies of cytogenetic abnormalities. This highlights the importance of greater standardization of cytogenetic methods, which should ideally include a synchronized culture 25 which improves chromosome morphology facilitating detection of subtle abnormalities such as inv (16) . A further potential influence upon reported CBF fusion gene frequencies relates to the age of the patient population subject to molecular screening, since it seems likely that cases harboring AML1-ETO or CBF␤-MYH11 in the absence of t(8;21) and inv(16)/t(16;16) will be more common in children and younger adults in whom at least 10-15% have CBF leukemia, 3, 24, 26 as opposed to older cohorts of patients in whom t(8;21) and inv (16) are relatively rare accounting for only 3% cases. 27 Therefore, the relatively low rates of cryptic AML1-ETO and CBF␤-MYH11 rearrangements reported by Rowe et al, 20 may relate to performance of cytogenetic analysis in specialist centers, combined with the inclusion of a significant proportion of elderly patients. Other aspects relating to the nature of the patient population also need to be taken into consideration in assessing the relative frequencies of CBF gene rearrangements. In some studies all unselected de novo AML cases were screened, whilst in others screening was targeted to particular subgroups. Interestingly, a recent study has suggested that the incidence of AML1-ETO-associated AML may vary geographically, being relatively uncommon amongst adult Spanish patients. 28 In addition to these factors, some variation in frequencies of cryptic CBF gene fusions may relate to the RT-PCR methodology with false negative results due to poor RNA quality, inefficiency of the reverse transcription step or suboptimal PCR primers and/or conditions. Indeed flawed primer design may preclude detection of CBF␤-MYH11 fusion genes resulting from rarer CBF␤ or MYH11 breakpoints. 29 False positive results may also be the consequence of misinterpretation of nonspecific amplification bands or result from PCR contamination.
The studies reported by Rowe et al 20 and Sarriera et al 21 raise a number of key issues. In particular, they highlight the importance of confirming detection of leukemia-associated fusion genes revealed by RT-PCR screening with an independent technique. This approach avoids errors due to PCR contamination and also controls for situations For some studies a range of frequencies for insertions, simple variants and complex cases is shown, since the experimental techniques used did not permit precise determination of the relative frequencies. ND, not detected; NR, not reported; NA, not applicable.
Table 2
Studies evaluating the role of molecular screening for detection of CBF␤-MYH11 associated AML
Study
Overall frequency For some studies a range of frequencies for insertions, simple variants and complex cases is shown, since the experimental techniques used did not permit precise determination of the relative frequencies. 30 and is therefore unlikely to be a key determinant of disease behavior. In the study by Sarriera et al, Western blotting was used to confirm RT-PCR evidence of an underlying AML1-ETO fusion in cases lacking the t(8;21). Whilst the AML1-ETO protein was not detected in 3/7 cases with available material considered to have cryptic AML1-ETO rearrangements, it seems unlikely that these were false-positive cases due to PCR contamination since RT-PCR assays were undertaken by two individuals obtaining concordant results. Metaphase FISH is generally favored over Western analysis for confirming cases with suspected cryptic fusion gene formation; however, its value is critically dependent upon the suitability of the probes. As indicated by Sarriera et al 21 and Rowe et al, 20 chromosome specific paints should not be used for this purpose, since they generally fail to detect cytogenetically cryptic insertion events. Therefore ideally, relatively small (40kb) locus-specific probes designed to detect the relevant AML1-ETO or CBF␤-MYH11 fusion gene should be used. Larger probes could potentially fail to detect small insertion events; this is likely to have accounted for the lack of detectable fusion signals in a study of two cases of AML1-ETO-positive AML with a del(9q) and normal appearing chromosomes 8 and 21 in which YAC probes were used for FISH analyses. 10 On the basis that APL patients with cryptic PML-RAR␣ fusions share the beneficial response to all-trans retinoic acid and favorable prognosis of those with documented t(15;17), 18, 19 it has been assumed that cases of AML with solely molecular evidence of an underlying AML1-ETO or CBF␤-MYH11 rearrangement are biologically similar to those with t(8;21) or inv(16)/t(16;16), respectively, predicting a favorable prognosis and should therefore receive the same treatment approach. This remains to be reliably established in large cohorts of patients; this is particularly pertinent in the light of the study by Sarriera et al 21 which proposed that patients with cryptic AML1-ETO gene rearrangements may have a poorer prognosis than those with t(8;21) given the caveat that the latter analysis was based upon perilously small numbers of patients.
Overall, studies to date support a role for routine cytogenetic analysis to be undertaken in parallel with molecular screening for AML1-ETO and CBF␤-MYH11 fusions. The relative benefit of molecular screening in terms of number of patients with CBF gene rearrangements detected will depend very much upon the age of the population to be screened, transit time to the cytogenetics laboratory, the methods used for karyotype analysis and the facility for central review. Although there has in some quarters been enthusiasm for adoption of molecular screening in preference to cytogenetic analysis, the latter technique should remain at the forefront of leukemia diagnosis since it provides a key prognostic indicator suitable for treatment stratification, detects t(8;21) and inv (16) in the majority of cases with molecular evidence of CBF gene involvement (Tables 1 and 2) , identifies additional cytogenetic abnormalities the functional significance of which is currently uncertain and has revealed novel rearrangements prompting subsequent characterization of their respective breakpoint regions (reviewed in Grimwade 31 ). Interestingly, the spectrum of additional cytogenetic changes detected in cases with cryptic AML1-ETO and CBF␤-MYH11 fusions is comparable to those with documented t(8;21) or inv (16) . Therefore, in cases of AML lacking the classic t(8;21) one should be alerted to the possibility of a cryptic AML1-ETO rearrangement on detection of del(9q) and/or loss of a sex chromosome, 10, 22, 32 or of a cryptic CBF␤-MYH11 fusion in the presence of +22, 13, 14, 16, 33, 34 particularly in conjunction with suggestive morphology. However, it should be appreciated that although cases with cryptic AML1-ETO gene fusions may share the distinctive morphological features associated with the t(8;21) and those with cryptic CBF␤-MYH11 fusions may exhibit an M4eo phenotype, this is not invariably the case 10, 11, 13, 14, 16, 23, 33, 35, 36 suggesting that molecular screening should not be solely targeted to such patients. Furthermore, the majority of cases of AML with del(9q) or +22 have been shown not to have underlying cryptic CBF gene rearrangements. 37 Summarizing the data presented in Table 1 , amongst 171 cases of AML1-ETO-associated AML, the t(8;21) was detected in 72%, whilst the fusion gene resulted from presumed or documented insertion events, simple variant translocations and complex rearrangements in 16-19%, 1-6% and 4-8%, respectively. Similarly, inv (16) or t (16;16) were detected in 112/143 (78%) cases of CBF␤-MYH11-positive AML, with insertions and complex rearrangements accounting for 13% and 1%, respectively (Table 2) . Even if detection rates for cryptic CBF gene Leukemia fusions are relatively low amongst cohorts of unselected de novo AML, molecular screening is still highly valuable. It not only serves to identify subgroups of patients who may not benefit from routine use of BMT in first CR, but also increases the numbers of patients that can be monitored by molecular means for minimal residual disease (MRD), which has been shown to be an independent prognostic factor facilitating more precise tailoring of therapy (reviewed in Ref. 38) . Therefore, routine molecular screening not only has the potential to improve patient care, but when considered in the context of the expenditure relating to transplant procedures renders this approach highly cost effective. A challenge for future studies is to reliably determine whether the outcome of patients with AML associated with cryptic AML1-ETO and CBF␤-MYH11 fusions is comparable to those with documented t(8;21) and inv (16) . This is a critical issue which can only be resolved through long-term follow-up of much larger cohorts of patients, although in the meantime some insights may be gained through quantitative RT-PCR analysis for MRD in cases with cryptic AML1-ETO or CBF␤-MYH11 in comparison to cases with cytogenetic evidence of their counterparts.
